Idiopathiás nephrosis szindróma gyermekkorban

Translated title of the contribution: Nephrotic syndrome in childhood

G. Reusz, Attila Szabó, Andrea Fekete

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Minimal change nephrosis, the main pediatric form of idiopathic nephrotic syndrome is usually a benign condition responsive to standard steroid treatment. However, relapses occur frequently leading to secondary steroid resistance in a small proportion of cases. Steroid resistant nephrotic syndrome presents mainly as focal segmental glomerulosclerosis. It represents about 8-10% of cases of pediatric idiopathic nephrotic syndrome. The prognosis of focal segmental glomerulosclerosis is bad, with the majority of cases evolving to terminal renal insufficiency within several years. Among the causes of idiopathic nephrotic syndrome are changes of cellular immunity, circulating plasma factors not fully identified yet and mutations of podocyte proteins. Podocyte mutations are responsible for the development of about one third of cases steroid resistant focal segmental glomerulosclerosis. Treatment of idiopathic nephrotic syndrome is determined by international guidelines. If initial steroid treatment is followed by multiple relapses, levamisole, cyclophosphamide and finally cyclosporine-A are used stepwise. In the case of steroid resistance podocyte mutations should be evaluated. If mutated, aggressive steroid treatment is contraindicated. Cases without mutations are candidates for an intensified steroid therapy and cyclosporine-A. Recurrence of focal segmental glomerulosclerosis following transplantation can be suspected in patients without podocyte mutations. Due to the crucial role of the presence of mutations in focal segmental glomerulosclerosis, genetic evalutation before aggressive immunosuppression and preceding transplantation should be introduced. Supportive treatment of idiopathic nephrotic syndrome consists of fluid and salt restriction, protein intake tailored to the protein losses, prevention of thrombosis and infection, and - mainly in steroid resistant cases - measures to prevent of premature atherosclerosis and deterioration of kidney function.

Original languageHungarian
Pages (from-to)2251-2260
Number of pages10
JournalOrvosi Hetilap
Volume147
Issue number47
Publication statusPublished - Nov 26 2006

Fingerprint

Nephrotic Syndrome
Steroids
Focal Segmental Glomerulosclerosis
Podocytes
Mutation
Recurrence
Cyclosporine
Therapeutics
Transplantation
Pediatrics
Nephrosis
Levamisole
Proteins
Cellular Immunity
Cyclophosphamide
Immunosuppression
Renal Insufficiency
Atherosclerosis
Thrombosis
Salts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reusz, G., Szabó, A., & Fekete, A. (2006). Idiopathiás nephrosis szindróma gyermekkorban. Orvosi Hetilap, 147(47), 2251-2260.

Idiopathiás nephrosis szindróma gyermekkorban. / Reusz, G.; Szabó, Attila; Fekete, Andrea.

In: Orvosi Hetilap, Vol. 147, No. 47, 26.11.2006, p. 2251-2260.

Research output: Contribution to journalArticle

Reusz, G, Szabó, A & Fekete, A 2006, 'Idiopathiás nephrosis szindróma gyermekkorban', Orvosi Hetilap, vol. 147, no. 47, pp. 2251-2260.
Reusz G, Szabó A, Fekete A. Idiopathiás nephrosis szindróma gyermekkorban. Orvosi Hetilap. 2006 Nov 26;147(47):2251-2260.
Reusz, G. ; Szabó, Attila ; Fekete, Andrea. / Idiopathiás nephrosis szindróma gyermekkorban. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 47. pp. 2251-2260.
@article{45f4d3ddca1242f1925559a8f8f535bd,
title = "Idiopathi{\'a}s nephrosis szindr{\'o}ma gyermekkorban",
abstract = "Minimal change nephrosis, the main pediatric form of idiopathic nephrotic syndrome is usually a benign condition responsive to standard steroid treatment. However, relapses occur frequently leading to secondary steroid resistance in a small proportion of cases. Steroid resistant nephrotic syndrome presents mainly as focal segmental glomerulosclerosis. It represents about 8-10{\%} of cases of pediatric idiopathic nephrotic syndrome. The prognosis of focal segmental glomerulosclerosis is bad, with the majority of cases evolving to terminal renal insufficiency within several years. Among the causes of idiopathic nephrotic syndrome are changes of cellular immunity, circulating plasma factors not fully identified yet and mutations of podocyte proteins. Podocyte mutations are responsible for the development of about one third of cases steroid resistant focal segmental glomerulosclerosis. Treatment of idiopathic nephrotic syndrome is determined by international guidelines. If initial steroid treatment is followed by multiple relapses, levamisole, cyclophosphamide and finally cyclosporine-A are used stepwise. In the case of steroid resistance podocyte mutations should be evaluated. If mutated, aggressive steroid treatment is contraindicated. Cases without mutations are candidates for an intensified steroid therapy and cyclosporine-A. Recurrence of focal segmental glomerulosclerosis following transplantation can be suspected in patients without podocyte mutations. Due to the crucial role of the presence of mutations in focal segmental glomerulosclerosis, genetic evalutation before aggressive immunosuppression and preceding transplantation should be introduced. Supportive treatment of idiopathic nephrotic syndrome consists of fluid and salt restriction, protein intake tailored to the protein losses, prevention of thrombosis and infection, and - mainly in steroid resistant cases - measures to prevent of premature atherosclerosis and deterioration of kidney function.",
keywords = "Focal segmental glomerulosclerosis, Idiopathic nephrotic syndrome, Minimal change nephrosis, Podocin, Podocyte, Transplantation",
author = "G. Reusz and Attila Szab{\'o} and Andrea Fekete",
year = "2006",
month = "11",
day = "26",
language = "Hungarian",
volume = "147",
pages = "2251--2260",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Idiopathiás nephrosis szindróma gyermekkorban

AU - Reusz, G.

AU - Szabó, Attila

AU - Fekete, Andrea

PY - 2006/11/26

Y1 - 2006/11/26

N2 - Minimal change nephrosis, the main pediatric form of idiopathic nephrotic syndrome is usually a benign condition responsive to standard steroid treatment. However, relapses occur frequently leading to secondary steroid resistance in a small proportion of cases. Steroid resistant nephrotic syndrome presents mainly as focal segmental glomerulosclerosis. It represents about 8-10% of cases of pediatric idiopathic nephrotic syndrome. The prognosis of focal segmental glomerulosclerosis is bad, with the majority of cases evolving to terminal renal insufficiency within several years. Among the causes of idiopathic nephrotic syndrome are changes of cellular immunity, circulating plasma factors not fully identified yet and mutations of podocyte proteins. Podocyte mutations are responsible for the development of about one third of cases steroid resistant focal segmental glomerulosclerosis. Treatment of idiopathic nephrotic syndrome is determined by international guidelines. If initial steroid treatment is followed by multiple relapses, levamisole, cyclophosphamide and finally cyclosporine-A are used stepwise. In the case of steroid resistance podocyte mutations should be evaluated. If mutated, aggressive steroid treatment is contraindicated. Cases without mutations are candidates for an intensified steroid therapy and cyclosporine-A. Recurrence of focal segmental glomerulosclerosis following transplantation can be suspected in patients without podocyte mutations. Due to the crucial role of the presence of mutations in focal segmental glomerulosclerosis, genetic evalutation before aggressive immunosuppression and preceding transplantation should be introduced. Supportive treatment of idiopathic nephrotic syndrome consists of fluid and salt restriction, protein intake tailored to the protein losses, prevention of thrombosis and infection, and - mainly in steroid resistant cases - measures to prevent of premature atherosclerosis and deterioration of kidney function.

AB - Minimal change nephrosis, the main pediatric form of idiopathic nephrotic syndrome is usually a benign condition responsive to standard steroid treatment. However, relapses occur frequently leading to secondary steroid resistance in a small proportion of cases. Steroid resistant nephrotic syndrome presents mainly as focal segmental glomerulosclerosis. It represents about 8-10% of cases of pediatric idiopathic nephrotic syndrome. The prognosis of focal segmental glomerulosclerosis is bad, with the majority of cases evolving to terminal renal insufficiency within several years. Among the causes of idiopathic nephrotic syndrome are changes of cellular immunity, circulating plasma factors not fully identified yet and mutations of podocyte proteins. Podocyte mutations are responsible for the development of about one third of cases steroid resistant focal segmental glomerulosclerosis. Treatment of idiopathic nephrotic syndrome is determined by international guidelines. If initial steroid treatment is followed by multiple relapses, levamisole, cyclophosphamide and finally cyclosporine-A are used stepwise. In the case of steroid resistance podocyte mutations should be evaluated. If mutated, aggressive steroid treatment is contraindicated. Cases without mutations are candidates for an intensified steroid therapy and cyclosporine-A. Recurrence of focal segmental glomerulosclerosis following transplantation can be suspected in patients without podocyte mutations. Due to the crucial role of the presence of mutations in focal segmental glomerulosclerosis, genetic evalutation before aggressive immunosuppression and preceding transplantation should be introduced. Supportive treatment of idiopathic nephrotic syndrome consists of fluid and salt restriction, protein intake tailored to the protein losses, prevention of thrombosis and infection, and - mainly in steroid resistant cases - measures to prevent of premature atherosclerosis and deterioration of kidney function.

KW - Focal segmental glomerulosclerosis

KW - Idiopathic nephrotic syndrome

KW - Minimal change nephrosis

KW - Podocin

KW - Podocyte

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=34249695386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249695386&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 2251

EP - 2260

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -